Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Moderna filed for FDA approval of its mRNA-1083 combination shot last year. The submission put the biotech on track to win ...

Despite Merck KGaA’s lupus drug failing to prove itself against one form of the autoimmune disease, the German drugmaker has ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

When mice implanted with metastasis-prone human cancer cells were treated with compounds that targeted ACBP’s activity, none ...

Medtronic plans to separate from its diabetes business and launch it as an independent company—one that will count more than ...

Having already worked with clinical trial sites in more than 14 states, CTAC will now take its work nationwide, the ...

French biotech OSE Immunotherapeutics is taking charge of a new project aimed at fast-tracking nanodrug development and ...

A Hong Kong-based developer of a catalog of urine-based tests for cancer, infectious diseases, women’s health and more has ...

Roivant has its own TYK2/JAK1 inhibitor in development in the form of brepocitinib, which the biopharma licensed from Pfizer ...

Philips is launching a new clinical trial aimed at reducing the amount of radiation used during coronary procedures, with an ...

Blueprint Medicines is revising a pact with VantAI again, this time adding a focus for historically “undruggable” targets and ...